scout
|Videos|January 31, 2019

First-Line Triplet in BRAF+ mCRC

An overview of the goals and design of the phase II single arm ANCHOR trial, which looks at the combination triplet regimen used in the BEACON study, encorafenib, binimetinib, and cetuximab, as first-line treatment for BRAFV600E-mutant metastatic colorectal cancer (mCRC).

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME